Abstract:Background Cardiac remodeling predisposes individuals to heart failure if the burden is not solved, and heart failure is a growing cause of morbidity and mortality worldwide. The cardiac extracellular matrix not only provides structural support, but also is a core aspect of the myocardial response to various biomechanical stresses and heart failure. MFAP4 (microfibrillar‐associated protein 4) is an integrin ligand located in the extracellular matrix, whose biological functions in the heart remain poorly understood. In the current study we aimed to test the role of MFAP4 in cardiac remodeling. Methods and Results MFAP4‐deficient (MFAP4 −/− ) and wild‐type mice were subjected to aortic banding surgery and isoproterenol to establish models of cardiac remodeling. We also evaluated the functional effects of MFAP4 on cardiac hypertrophy, fibrosis, and cardiac electrical remodeling. The expression of MFAP4 was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. After challenge of 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol, MFAP4 −/− mice exhibited lower levels of cardiac fibrosis and fewer ventricular arrhythmias than wild‐type mice. However, there was no significant effect on cardiomyocyte hypertrophy. In addition, there was no significant difference in cardiac fibrosis severity, hypertrophy, or ventricular arrhythmia incidence between wild‐type‐sham and knockout‐sham mice. Conclusions These findings are the first to demonstrate that MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. In addition, MFAP4 deficiency had no significant effect on cardiac fibrosis, hypertrophy, or ventricular arrhythmia in the sham group in this study. Nonstandard Abbreviations and Acronyms AB aortic banding Ad‐shMFAP4 pDKD‐CMV‐eGFP‐U6‐shRNA‐MFAP4 Ad‐shRNA pDKD‐CMV‐eGFP‐U6‐shRNA PCL pacing cycle length MFAP4 microfibrillar‐associated protein 4 VA ventricular arrhythmias Ad‐MFAP4 Adenovirus vector pAdeno‐EF1A(S)‐mNeonGreen‐CMVMfap4‐3FLAG Clinical Perspective What Is New? For the first time we have defined the expression of MFAP4 (microfibrillar‐associated protein 4) was increased in the animal cardiac remodeling models induced by pressure overload and isoproterenol. MFAP4 deficiency inhibits cardiac fibrosis and ventricular arrhythmias after challenge with 8 weeks of aortic banding or 2 weeks of intraperitoneal isoproterenol but does not significantly affect the hypertrophy response. What Are the Clinical Implications? MFAP4 may act as a novel therapeutic target for the upstream prevention of cardiac remodeling and heart failure. Heart failure (HF) is the common ultimate outcome of different types of cardiovascular diseases, and is a growing public health problem associated with high hospitalization and mortality. 1 , 2 , 3 , 4 Cardiac remodeling is an adaptive cellular response to various kinds of biomechanical stresses or hemodynamic overload, that involves a series of structural and functional alterations, including increase in the size and/or thickness of cardiomyocytes and the left ventricle, perivascular and interstitial fibrosis, various types of ventricular and atrial arrhythmias and so on. 5 , 6 Cardiac remodeling predisposes a patient to HF if the burden is not solved, and can be divided into structural remodeling and electrical remodeling. Structural remodeling includes cardiac fibrosis and cardiac hypertroph -Abstract Truncated-

The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy

Increased Myocardial Stiffness Activates Cardiac Microvascular Endothelial Cell Via VEGF Paracrine Signaling in Cardiac Hypertrophy

Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes.

Plasma membrane Ca2+-ATPase regulates Ca2+ signaling and the proliferation of airway smooth muscle cells

Abstract 159: Ablation of the Hypertension Candidate Gene ATP2B1 Leads To Deficient Calcium Cycling, Systolic Dysfunction and Heart Failure Following Pressure Overload

Integrative Physiology Role of Ca /Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy

Microtubule Associated Protein 4 Phosphorylation Leads to Pathological Cardiac Remodeling in Mice.

Abstract 17221: AMPK Regulation of Microtubule Dynamics in Cardiac Hypertrophy

Haplodeficiency of Activin Receptor-Like Kinase 4 Alleviates Myocardial Infarction-Induced Cardiac Fibrosis and Preserves Cardiac Function

Activated FMS‐like Tyrosine Kinase 3 Ameliorates Angiotensin II‐induced Cardiac Remodelling

The δA isoform of calmodulin kinase II mediates pathological cardiac hypertrophy by interfering with the HDAC4-MEF2 signaling pathway.

Abstract 109: PI3Kγ Regulates Release of Myocyte-derived Factors Responsible for Myofibroblast Differentiation and Cardiac Fibrosis

Carboxyl-Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway.

Protein Kinase A Is a Master Regulator of Physiological and Pathological Cardiac Hypertrophy

Deletion of Microfibrillar-Associated Protein 4 Attenuates Left Ventricular Remodeling and Dysfunction in Heart Failure.

Role of Ca2+/calmodulin-stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy.

Abstract 13694: Hsf1 Attenuates Pressure Overload Induced-cardiac Fibrosis via Inhibiting Smad3 Phosphorylation and Nuclear Translocation

Abstract P234: CTMP Negatively Regulates Pathological Cardiac Hypertrophy via Akt-dependent Manner

AMPK Attenuates Microtubule Proliferation in Cardiac Hypertrophy.

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway

Macrophage Migration Inhibitory Factor Deletion Exacerbates Pressure Overload–Induced Cardiac Hypertrophy Through Mitigating Autophagy